- Resverlogix Corp. (RVX) has published an article highlighting the benefits of apabetalone in non-alcoholic fatty liver disease
- The article was published in the American Journal of Preventive Cardiology
- The article presents a post-hoc analysis of BETonMACE data, which demonstrates that apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis
- Apabetalone (RVX-208) is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action
- Resverlogix Corp. is a Calgary-based late-stage biotechnology company and a world leader in epigenetics
- Resverlogix Corp. was up 16.00 per cent, trading at $0.29 as at 2:05 PM ET
Resverlogix Corp. (RVX) has published an article highlighting the benefits of apabetalone in non-alcoholic fatty liver disease.
The article is entitled “Reduction in the Risk of Major Adverse Cardiovascular Events with the BET Protein Inhibitor Apabetalone in Patients with Recent Acute Coronary Syndrome, Type 2 Diabetes, and Moderate to High Likelihood of Non-Alcoholic Fatty Liver Disease.”
The article was published in the American Journal of Preventive Cardiology.
The article presents a post-hoc analysis of BETonMACE data, which demonstrates that apabetalone treatment improves cardiac outcomes and liver fibrosis scores in patients with moderate-to-high likelihood of advanced liver fibrosis.
“In this patient group, apabetalone treatment was associated not only with fewer negative cardiovascular outcomes, but also relative improvements in liver fibrosis score,” said Dr. Peter P. Toth, Director of Preventive Cardiology at CGH Medical Center in Sterling, IL, and the corresponding author of the article.
“These promising findings make the case for a larger study of non-alcoholic fatty liver disease patients to better understand the scope of apabetalone’s benefit,” he added.
Highlights of the publication include that angulo fibrosis score (FS) has a validated association with non-alcoholic fatty liver disease prevalence and that BETonMACE participants with an elevated FS had higher incidences of major adverse cardiac events (MACE) and hospitalizations due to heart failure (HHF).
In addition, the publication noted that apabetalone treatment reduced the hazard of HHF (HR=0.53, p=0.01), as well as a composite MACE and HHF (HR=0.76, p=0.03) in BETonMACE participants with elevated FS.
When compared to the placebo group, patients who received apabetalone treatment saw significantly smaller increases in their liver fibrosis scores.
Apabetalone (RVX-208) is a first-in-class, small molecule, therapeutic candidate with an epigenetic mechanism of action.
It is a BD2 (bromodomain) selective BET (bromodomain and extra-terminal) inhibitor that works in preventing and treating disease progression by regulating the expression of disease-causing genes.
Resverlogix Corp. is a Calgary-based late-stage biotechnology company and a leader in epigenetics focusing on developing therapies for the benefit of patients with chronic disease.
Resverlogix Corp. was up 16.00 per cent, trading at $0.29 as at 2:05 PM ET.